ABSTRACT
Over two dozen spliceosome proteins are involved in human diseases, also referred to as spliceosomopathies. WBP4 (WW Domain Binding Protein 4) is part of the early spliceosomal complex, and was not described before in the context of human pathologies. Ascertained through GeneMatcher we identified eleven patients from eight families, with a severe neurodevelopmental syndrome with variable manifestations. Clinical manifestations included hypotonia, global developmental delay, severe intellectual disability, brain abnormalities, musculoskeletal and gastrointestinal abnormalities. Genetic analysis revealed overall five different homozygous loss-of-function variants in WBP4. Immunoblotting on fibroblasts from two affected individuals with different genetic variants demonstrated complete loss of protein, and RNA sequencing analysis uncovered shared abnormal splicing patterns, including enrichment for abnormalities of the nervous system and musculoskeletal system genes, suggesting that the overlapping differentially spliced genes are related to the common phenotypes of the probands. We conclude that biallelic variants in WBP4 cause a spliceosomopathy. Further functional studies are called for better understanding of the mechanism of pathogenicity.
Competing Interest Statement
HMS is an employee of Geneyx Genomics. Other authors declare no conflict of interest.
Funding Statement
This work is supported by Estonian Research Council grants PRG471 and PSG774. The Broad Institute Center for Mendelian Genomics (UM1HG008900) is funded by the National Human Genome Research Institute with supplemental funding provided by the National Heart, Lung, and Blood Institute under the Trans-Omics for Precision Medicine (TOPMed) program and the National Eye Institute. MHW is supported by K23HD102589.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Hadassah Medical Organization gave ethical approval for this work (protocol 0306-10-HMO). The Research Ethics Committee of the University of Tartu gave ethical approval for this work (Certificate No 269/M-18 on 17.04.2017).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All analyzed data consists of patient's personal data and is stored according to regulations of the institutions. Pseudonymized data is available on request. The ClinVar accession number for the DNA variants data are: SCV003922044 WBP4 NM_007187.5 c.499delA SCV003922045 WBP4 NC_000013.11 g.41074134_41090164del SCV003922046 WBP4 NM_007187.5 c.668C>G SCV003922047 WBP4 NM_007187.5 c.944delC SCV003922048 WBP4 NM_007187.5 c.440-1G>A.
